Biologics for the treatment of moderate- to-severe ulcerative colitis in pediatric patients
Lindsey G Albenberg, Petar Mamula, Judith R KelsenDivision of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA, USAAbstract: Ulcerative colitis (UC) is a chronic, inflammatory disease of the large intestine. In pediatric patients, UC is a...
Saved in:
Main Authors: | Albenberg LG (Author), Mamula P (Author), Kelsen JR (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2012-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
by: Freeman HJ
Published: (2013) -
Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
by: Nastya Kassir, et al.
Published: (2022) -
Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
by: Anita Moein, et al.
Published: (2022) -
Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis
by: M. Galván-Banqueri, et al.
Published: (2015) -
Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
by: Napolitano M, et al.
Published: (2022)